ATE292975T1 - Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii - Google Patents

Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii

Info

Publication number
ATE292975T1
ATE292975T1 AT98908008T AT98908008T ATE292975T1 AT E292975 T1 ATE292975 T1 AT E292975T1 AT 98908008 T AT98908008 T AT 98908008T AT 98908008 T AT98908008 T AT 98908008T AT E292975 T1 ATE292975 T1 AT E292975T1
Authority
AT
Austria
Prior art keywords
tetrahydolipstatin
diabetes
treatment
type
Prior art date
Application number
AT98908008T
Other languages
English (en)
Inventor
Jonathan Brian Hauptman
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21894047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE292975(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE292975T1 publication Critical patent/ATE292975T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT98908008T 1997-02-05 1998-01-29 Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii ATE292975T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3738397P 1997-02-05 1997-02-05
PCT/EP1998/000468 WO1998034630A1 (en) 1997-02-05 1998-01-29 Use of gastrointestinal lipase inhibitors

Publications (1)

Publication Number Publication Date
ATE292975T1 true ATE292975T1 (de) 2005-04-15

Family

ID=21894047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98908008T ATE292975T1 (de) 1997-02-05 1998-01-29 Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii

Country Status (28)

Country Link
US (1) US6147108A (de)
EP (1) EP1017408B1 (de)
JP (1) JP2001509173A (de)
KR (1) KR100479968B1 (de)
CN (1) CN1154505C (de)
AR (1) AR011106A1 (de)
AT (1) ATE292975T1 (de)
AU (1) AU740375B2 (de)
BR (1) BR9807655A (de)
CA (1) CA2278854C (de)
CZ (1) CZ295567B6 (de)
DE (1) DE69829763T2 (de)
DK (1) DK1017408T3 (de)
ES (1) ES2239799T3 (de)
HK (1) HK1025251A1 (de)
HU (1) HU230834B1 (de)
ID (1) ID22650A (de)
IL (1) IL131007A0 (de)
ME (1) ME00578A (de)
NO (1) NO324452B1 (de)
NZ (1) NZ336755A (de)
PL (1) PL191222B1 (de)
PT (1) PT1017408E (de)
RU (1) RU2201272C2 (de)
TR (1) TR199901853T2 (de)
WO (1) WO1998034630A1 (de)
YU (1) YU34199A (de)
ZA (1) ZA98753B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID22650A (id) * 1997-02-05 1999-12-02 Hoffmann La Roche Penggunaan penghambat-penghambat lipase usus lambung
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
ES2324280T3 (es) 2000-03-14 2009-08-04 Unilever N.V. Dominios variables de la cadena pesada de anticuerpos frente a lipasas dieteticas humanas y sus usos.
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US9174176B2 (en) 2003-01-09 2015-11-03 Disperse Systems, Inc. Ultrasonic dispersion apparatus, system, and method
US7510849B2 (en) * 2004-01-29 2009-03-31 Glucolight Corporation OCT based method for diagnosis and therapy
AU2005269753B2 (en) 2004-07-19 2011-08-18 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
US8036727B2 (en) 2004-08-11 2011-10-11 Glt Acquisition Corp. Methods for noninvasively measuring analyte levels in a subject
US7254429B2 (en) 2004-08-11 2007-08-07 Glucolight Corporation Method and apparatus for monitoring glucose levels in a biological tissue
JP2008537903A (ja) 2005-04-13 2008-10-02 グルコライト・コーポレーシヨン Octが基になった血糖モニターのデータ処理および較正方法
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
PL2036575T3 (pl) * 2007-09-12 2011-02-28 Mader S R L Kompozycje farmaceutyczne do stosowania doustnie w leczeniu pacjentów dotkniętych otyłością
EP2219614A1 (de) * 2007-10-15 2010-08-25 Inventis DDS Pvt Limited Pharmazeutische zusammensetzung von orlistat
PT2203181T (pt) 2007-10-16 2018-05-10 Biocon Ltd Uma composição farmacêutica sólida para administração por via oral e o seu processo de fabrico
US8571617B2 (en) 2008-03-04 2013-10-29 Glt Acquisition Corp. Flowometry in optical coherence tomography for analyte level estimation
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
FR3017536B1 (fr) * 2014-02-18 2017-05-26 Univ La Rochelle Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
JP2019515654A (ja) * 2016-03-16 2019-06-13 ザ ジェイ. デヴィッド グラッドストーン インスティテューツ 肥満及び/又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
US20190022061A1 (en) * 2017-07-21 2019-01-24 Kieu Hoang Statins (Atorvastatin) can lower blood sugar level in diabetic

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) * 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5130333A (en) * 1990-10-19 1992-07-14 E. R. Squibb & Sons, Inc. Method for treating type II diabetes employing a cholesterol lowering drug
US5190970A (en) * 1990-10-19 1993-03-02 E. R. Squibb & Sons, Inc. Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5345056A (en) * 1991-12-12 1994-09-06 Motorola, Inc. Plasma based soldering by indirect heating
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JP3532999B2 (ja) * 1995-03-24 2004-05-31 株式会社ロッテ 新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
JPH09227398A (ja) * 1996-02-20 1997-09-02 Zeria Pharmaceut Co Ltd 抗肥満剤
ID22650A (id) * 1997-02-05 1999-12-02 Hoffmann La Roche Penggunaan penghambat-penghambat lipase usus lambung
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions

Also Published As

Publication number Publication date
PL191222B1 (pl) 2006-03-31
WO1998034630A1 (en) 1998-08-13
BR9807655A (pt) 2000-02-15
DE69829763D1 (de) 2005-05-19
HK1025251A1 (en) 2000-11-10
NZ336755A (en) 2001-06-29
HUP0001014A2 (hu) 2000-08-28
EP1017408A1 (de) 2000-07-12
AU6616998A (en) 1998-08-26
PL334975A1 (en) 2000-03-27
RU2201272C2 (ru) 2003-03-27
EP1017408B1 (de) 2005-04-13
US6147108A (en) 2000-11-14
DK1017408T3 (da) 2005-08-01
IL131007A0 (en) 2001-01-28
ES2239799T3 (es) 2005-10-01
CA2278854C (en) 2014-03-04
NO993717D0 (no) 1999-07-30
PT1017408E (pt) 2005-07-29
HU230834B1 (hu) 2018-07-30
YU34199A (sh) 2002-08-12
JP2001509173A (ja) 2001-07-10
CN1246798A (zh) 2000-03-08
AU740375B2 (en) 2001-11-01
CZ295567B6 (cs) 2005-08-17
CA2278854A1 (en) 1998-08-13
ME00578A (en) 2011-12-20
NO993717L (no) 1999-10-04
NO324452B1 (no) 2007-10-22
ZA98753B (en) 1998-08-05
ID22650A (id) 1999-12-02
HUP0001014A3 (en) 2000-12-28
KR20000070733A (ko) 2000-11-25
KR100479968B1 (ko) 2005-03-30
AR011106A1 (es) 2000-08-02
CZ265199A3 (cs) 2000-02-16
CN1154505C (zh) 2004-06-23
DE69829763T2 (de) 2006-04-13
TR199901853T2 (xx) 1999-12-21

Similar Documents

Publication Publication Date Title
DE69829763D1 (de) Verwendung von tetrahydolipstatin in der behandlung von diabetes typ ii
DE69817446D1 (de) Behandlung von diabetes
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
ATE355840T1 (de) Behandlung der diabetes mit thiazolidindione und metformin
ATE298241T1 (de) Behandlung von atemstillstand im schlaf
ATE256463T1 (de) Pharmazeutische zubereitung zur verwendung in der behandlung von diabetes
ATE110556T1 (de) Verbesserungen bei der behandlung von zähnen.
EE9900345A (et) Sulfonüülkarbamiidi ja glitasooni sünergistilised kombinatsioonid diabeedi raviks
DE122012000017I1 (de) Neuartige form von s-omeprazol.
ATE204754T1 (de) Pharmazeutische zusammensetzung von metformin und fibrat, und ihre verwendung zur behandlung von hyperglykämie
DE69905906D1 (de) Kombination von zwei oder mehreren wirkstoffen unter verwendung von mikrokapsel-formulierungen
DE50012379D1 (de) Verwendung von nanoskaligen antischuppenwirkstoffen
DE69804659D1 (de) 21-hydro-6,19-oxidoprogesterone (21oh-60p) und deren verwendung als arzneimittel zur behandlung von glukokortikoidüberschuss
DE69128941D1 (de) Verwendung von angiotensin-ii-rezeptorantagonisten in der behandlung der diabetischen nephropathie
DE69821998D1 (de) Verringerung von geistartefakten
DE59915061D1 (de) Herstellung von strukturierten elektroden
DE69123178D1 (de) Verwendung von Uridin zur pharmakologischen Behandlung der peripheren Komplikationen bei Diabetes
DE69534632T2 (de) Clotrimazol-Metaboliten bei der Behandlung von Sichelzellenkrankheit
ATE213149T1 (de) Reinigende kosmetische zusammensetzung und verwendung
DE59810482D1 (de) Schleifen von garnituren
DE69618264D1 (de) Verbesserungen bei der Herstellung von Kristallsubstraten
DE69924488D1 (de) Verwendung von optisch reinem (-) norcisapride in der behandlung des reizdarmsyndroms
DE69837089D1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
ATE366577T1 (de) Behandlung der diabetes mit thiazolidindione und sulphonylurea
DE59812720D1 (de) Verwendung von phytostenol enthaltender wirkstoffmischungen zur herstellung von hypocholesterinämischen mitteln

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1017408

Country of ref document: EP